ENCYSIVE Pharmaceuticals About
Encysive Encysive Pharmaceuticals is a pharmaceutical
company that discovers, develops and commercializes small molecule drugs aimed
at cardiovascular and inflammatory diseases. Encysive has one of the broadest
product pipelines in the sector. With this strong foundation,they are well positioned
to become a recognized leader in the discovery, development, and marketing of
differentiated drugs that improve survival and quality of life for victims of
serious cardiovascular and inflammatory diseases such as: • heparin-induced thrombocytopenia
(HIT) • pulmonary hypertension • essential hypertension • chronic heart failure
• multiple sclerosis
• asthma • atherosclerosis
Argatroban (FDA approved) was developed
to treat heparin-induced thrombocytopenia (HIT), a serious immune reaction to
heparin that causes abnormal clotting and often leads to limb amputation and even
death. Thelin (sitaxsentan), is an endothelin receptor antagonist
being developed as a treatment for pulmonary arterial hypertension (PAH). BIMOSIAMOSE
Clinical trials are now underway (with corporate partners) with Bimosiamose
as an inhaled therapy for asthma. Clinical trials are also ongoing with Bimosiamose
for treating psoriasis and atopic dermatitis. TBC3711 Based on the
positive data received for sitaxsentan, their first endothelin A antagonist, Encysive
believes TBC3711 holds promise as a next generation compound.
More
on Encysive Key
Statistics for Encysive
Basic
Chart for Encysive